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ABSTRACT
Aim of FAST-MI 2010 To gather data on characteristics,
management and outcomes of patients hospitalised for
acute myocardial infarction (AMI) at the end of 2010 in
France.
Interventions To provide cardiologists and health
authorities national and regional data on AMI
management every 5 years.
Setting Metropolitan France. 213 academic (n¼38),
community (n¼110), army hospitals (n¼2), private
clinics (n¼63), representing 76% of centres treating AMI
patients. Inclusion from 1 October 2010.
Population Consecutive patients included during
1 month, with a possible extension of recruitment up to
one additional month (132 centres); 4169 patients
included over the entire recruitment period, 3079 during
the ﬁrst 31 days; 249 additional patients declining
participation (5.6%).
Startpoints Consecutive adults with ST-elevation and
non-ST-elevation AMI with symptom onset #48 h.
Patients with AMI following cardiovascular procedures
excluded.
Data capture Web-based collection of 385 items
(demographic, medical, biologic, management data)
recorded online from source ﬁles by external research
technicians; case-record forms with automatic quality
checks. Centralised biology in voluntary centres to collect
DNA samples and serum. Long-term follow-up organised
centrally with interrogation of municipal registry ofﬁces,
patients’ physicians, and direct contact with the patients.
Data quality Data management in Toulouse University.
Statistical analyses: Universite ´ Paris Descartes,
Universite ´ de Toulouse, Universite ´ Pierre et Marie Curie-
Paris 06, Paris.
Endpoints and linkages to other data In-hospital
events; cardiovascular events, hospital admissions and
mortality during follow-up. Linkage with Institute for
National Statistics.
Access to data Available for research to any
participating clinician upon request to executive
committee (fastmi2010@yahoo.fr).
BACKGROUND
Cardiovascular mortality has recently declined,
even in countries with a low prevalence of coronary
artery disease, such as France.
1 This is attributed to
both improved primary prevention and improved
treatment of established cardiovascular disease.
Observational data collected from cohorts of
patients presenting with acute myocardial infarc-
tion (AMI) give the opportunity to determine
whether the practice guidelines derived from the
results of clinical trials have translated into changes
in everyday practice. They also permit to make
a link between different management strategies and
clinical outcomes. Registries such as the interna-
tional Global Registry of Acute Coronary Events
(GRACE),
2 3 the Euro Heart Survey programme
4 or
the USA, Swedish or British Myocardial Ischaemia
National Audit Project (MINAP) national regis-
tries
5e7 have been particularly helpful to improve
our knowledge in this ﬁeld. Some of these registries,
however, suffer from a relative lack of representa-
tiveness, while others are highly representative but
cannot collect extensive clinical data.
Every 5 years since 1995, cohorts of patients
hospitalised for AMI in France over a 1-month
period (see online supplementary ﬁles) have been
constituted, to assess their management and
outcomes.
8e10 All of these registries included at
least 60% of all institutions taking care of patients
with AMI, and the patients were followed for at
least 1 year.
In 2005, the FAST-MI registry was designed to
collect extensive data in patients hospitalised for
AMI and to follow the cohort thus constituted for
a period of up to 10 years.
8 A distinctive feature of
FAST-MI is that all medications delivered at the
acute stage, as well as the doses used are recorded.
In addition a bio-bank collecting serum and DNA
samples is also constituted for the purpose of
pharmacogenetic studies.
11 FAST-MI 2010 was set-
up to conduct a new survey with similar objectives
as the 2005 registry.
AIM
The aims of FAST-MI 2010 were to provide an
extensive description of the population of patients
admitted for AMI throughout the French territory,
to determine whether differences in terms of popu-
lation characteristics existedacross regions, to assess
themanagementofthepatientssufferingfromAMI,
and to determine the implementation of practice
guidelines in a real world setting. Other objectives
weretoassessthecorrelationsbetweenmanagement
strategies and in-hospital outcomes, to determine
the correlations between genetic polymorphisms
and morbidity-mortality in relation with the effects
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Registryof medications, and to determine the relationships between
biomarkersandmorbidity-mortalityafterMI.Also,FAST-MIwill
enable historic comparisons with the previous French cohorts
constituted since 1995 and will document the long-term (up to
10 years) outcomes of patients presenting with AMI at the end of
2010, in relation with early and long-term management.
Organisation and funding
Type of study
Prospective, multi-centre observational study in continental
France and Corsica. FAST-MI 2010 is a registry of the French
Society of Cardiology, supported by the Société Française de
Médecine d’Urgence, SAMU de France, the Collège National des
Cardiologues des Hôpitaux and the Collège National des
Cardiologues Français.
Funding and data propriety
The study is sponsored by the French Society of Cardiology and
funded by unrestricted grants of the following companies: MSD,
and AstraZeneca, the Daiichi-Sankyo-Eli-Lilly alliance, Glaxo-
Smith-Kline, Novartis, and sanoﬁ-aventis. Complementary
grants will be sought for dedicated research projects within the
main study.
Conduct of the registry and legal issues
The cardiologists who participated in the registry were not
supposed to modify their therapeutic approach in any way. In
the centres participating in the bio-bank, however, an additional
10e60 ml blood sample was collected at the time the routine
blood sample was drawn.
Written informed consent was provided by each patient for
participating in the study. The data from patients dying early
(ie, before informed consent was obtained), were collected and
recorded in the database, unless opposed to by the patient’s next
of kin when informed.
The study was conducted in compliance with Good Clinical
Practice, French law and the French data protection law. The
protocol was reviewed and approved by the Committee for the
Protection of Human Subjects (CPP) of Saint Louis University
Hospital Paris Ile de France IV. The data recorded and the way
they are handled and stored were reviewed and approved by
the Comité consultatif sur le traitement de l’information en
matière de recherche dans le domaine de la santé (CCTIRS) and
the Commission Nationale Informatique et Liberté (CNIL).
Clinicaltrials.gov identiﬁer: NCT01237418.
Patients
Inclusion criteria
Each patient had to meet the following criteria:
1) Man or woman aged 18 years or over.
2) Admitted within 48 h of symptom onset to an intensive care
unit (ICU) or a Cardiology department for an AMI
characterised by elevation of troponins or CK-MB associated
with at least one of the following:
e symptoms compatible with myocardial ischaemia,
e development of new abnormal Q waves,
e ST-T changes compatible with myocardial ischaemia (ST
segment elevation or depression, Twave inversion);
3) Having agreed to take part into the study.
ST-segment elevation myocardial infarction (STEMI) was
diagnosed when ST elevation $1 mm was seen in at least two
contiguous leads in any location on the index or qualifying ECG,
or when presumed new left bundle branch block or documented
new Q waves were observed.
In the absence of ST-segment elevation, patients meeting the
inclusion criteria were considered to have NSTEMI.
Patients who died very early after admission and for whom
cardiac markers were not measured were included if they had
compatible signs or symptoms associated with typical,
unequivocal STchanges. Patients admitted after resuscitation of
a cardiac arrest were included only if the cardiac arrest had been
preceded by chest pain suggestive of AMI, having justiﬁed a call
to emergency services.
Patients participating in clinical trials could be included in the
registry, and information on trial participation was recorded.
Exclusion criteria
Exclusion criteria were: AMI with symptom onset >48 h from
ﬁrst call, unstable angina, iatrogenic AMI immediately following
cardiovascular procedures (patients with late stent thrombosis,
deﬁned as stent thrombosis occurring after hospital discharge
could be included), and diagnosis of AMI refuted in favour of
alternative diagnoses, such as acute myocarditis.
Participating centres
A list of all intensive care or coronary care units admitting patients
with AMI in academic institutions, general hospitals, army
hospitals and private clinics was established at the beginning of
2010. The physicians in charge were then asked to participate in
the study. In all, 279 centres were listed, 224 of which initially
accepted to participate in the study and 213 actively participated,
including one general hospital which received no AMI patient
during the 1-month study period. Participation rate was 76% and
the centres were distributed across the whole country (ﬁgure 1).
In addition, approximately 100 further centres could receive
AMI patients at their emergency rooms, but referred these
patients to other institutions. These centres were not asked to
participate in the registry, as the patients were included at the
‘receiving’ institutions.
The participating centres comprised: 111 general hospitals, 49
private clinics, 13 private not-for-proﬁt clinics, 38 academic
hospitals, and 2 army hospitals.
Recruitment
Patients were recruited consecutively from ICU/cardiology
departments over a period of one month (from 1 October 2010).
A physician was responsible for study recruitment in each
centre. A list of all patients admitted within 48 h of symptom
onset for a suspicion of ACS was established at each institution,
and inclusion/exclusion criteria were checked. A computerised
case record form (CRF) was ﬁlled-in for each eligible patient,
based on the hospital records and additional speciﬁc question-
naires. Data were recorded on-line by dedicated research tech-
nicians from a contract research organisation (CRO) (ICTA,
Fontaine-lès-Dijon, France) who went to each centre on
a weekly basis. In the case of incomplete data from the source
patient ﬁles, the research technicians contacted the local inves-
tigator to obtain the missing information.
Recruitment could extend up to 2 months in the centres
willing to do so. The population included during the ﬁrst month
by the totality of participating centres is used as illustrative of
current management and outcomes on the scale of the whole
country, while the whole population will be used to answer
speciﬁc medical interrogations on a larger sample.
The data
What is recorded?
Cardiovascular and non-cardiovascular medical history, risk
factors, and clinical course, including symptoms, admission
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Registryand worst Killip class, therapeutic management in the pre-
hospital setting, during the ﬁrst 48 h, during the hospital stay
and at discharge, were recorded. Left ventricular ejection frac-
tion, when assessed at entry and at any time during the
hospital stay was recorded. Routine laboratory results on
admission were collected. All in-hospital complications were
recorded. In all, the electronic CRF comprised 385 items, to
which was added information on medications administered
before the index event, pre-hospital, during the ﬁrst 24 and 48 h
and at hospital discharge; for oral medications, doses were
recorded.
In 131 centres, a biology substudy collected blood and serum
samples for the assessment of DNA, RNA (120 Centres) and
centralised measurement of biological markers (77 Centres).
Patients’ follow-up
Follow-up data are collected by research technicians based at the
French Society of Cardiology (SFC) under the supervision of the
Unité de Recherche Clinique (URC-EST) of Assistance Publique-
Hôpitaux de Paris (APHP), using the following sequential
procedure, which was implemented for the follow-up of patients
participating in the FAST-MI 2005 registry: (1) consulting the
registry ofﬁces of the patients’ birthplaces for death certiﬁcates;
(2) contacting the patients’ general practitioners and/or cardi-
ologists; and (3) contacting the patients or their relatives. In
many instances, written contact is followed by telephone
interviews with the patients or their family.
For each reported event leading to hospitalisation or death,
hospital discharge reports are sought and analysed by at least
one physician from the research team. All cases of cardiovascular
events are centrally reviewed by at least one physician. We will
speciﬁcally collect information on the occurrence of acute
coronary syndromes, myocardial revascularisation, hospital-
isation for heart failure, stroke, bleeding events requiring
hospitalisation, hospitalisation for cancer. Cases in which the
ﬁnal diagnosis appears unclear or debatable are reviewed by
a three-member critical events committee.
Data quality
The quality of the data was insured by automated data checks
when the electronic CRF were ﬁlled-in, and by the fact that all
the data entered were veriﬁed, and modiﬁed if necessary, by
external research assistants. This methodology had already been
used for the FAST-MI 2005 survey with research assistants from
the same CRO and an external audit in three of 21 regions
showed data concordance in >90% of the cases.
Completeness of the data was adequate for most variables (eg,
missing values <4% for height and weight; <2% for admission
blood pressure and heart rate; <0.2% for risk factors or cardio-
vascular history; GRACE score calculated in 94.5%).
Once entered into the electronic CRF, data were stored in
a central database at the SFC, Paris. Data management is
ensured in conjunction between the SFC and the cardiology
departments of Toulouse and HEGP university hospitals.
Use of the data and cross-linkage
Data are available for research to any participating clinician
submitting an analysis plan to the executive committee
Figure 1 Geographical distribution of
the centres participating in FAST-MI
2010.
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Registry(fastmi2010@yahoo.fr). In addition, any centre can claim access
to its own data.
The database will be cross-linked with the French Institute for
National Statistics and the French national death database
(CepiDC) to gather additional information on the cause of
death.
Finally, to evaluate changes in practice in France over the past
ﬁfteen years, individual data from the 1995, 2000, 2005 and 2010
registries will be merged in a common database.
Statistical analyses
For quantitative variables, means, standard deviations, and
minimum and maximum values are calculated. In addition,
medians with the IQR are calculated for some variables. Discrete
variables are presented as percentages. Comparisons are made
with chi-square or Fisher’ s exact tests for discrete variables, and
by unpaired T tests, ManneWhitney U tests, Wilcoxon sign-
rank tests or one-way analyses of variance for continuous vari-
ables. Odds and hazard ratios are given with their 95% CIs.
Multivariate analyses of predictors of short-term outcome (in-
hospital, and 30 days) will use multiple logistic regression
analysis.
Long-term survival curves will be estimated using the Kaplan
Meier method and comparisons will be made using log-rank
tests. Independent correlates of survival will be determined
using a multivariate Cox model. Variables included in the ﬁnal
multivariate models will comprise those with a signiﬁcance level
<0.15 in the univariate analyses, unless otherwise stated. For
speciﬁc analyses regarding management options, propensity
scores will be calculated using multiple logistic regression anal-
yses and propensity-score-matched cohorts will be constructed.
For genetic analyses, all single-nucleotide polymorphisms
evaluated will be tested for deviation from HardyeWeinberg
equilibrium with the use of c
2 tests.
Statistical analyses are performed at Université Paris Descartes
(Nicolas Danchin, MD, PhD), Université of Toulouse (Jean
Ferrières, MD, PhD, Vincent Bataille, PhD), and Université Pierre
et Marie Curie Paris 06 (supervised by Tabassome Simon, MD,
Figure 2 Flow chart of the inclusion process.
Table 1 Main baseline characteristics
Whole population
(N[3079), N (%)
NSTEMI (N[1306),
N (%)
STEMI or presumed
new LBBB (N[1773), N (%) p Value
Centre 0.038
Academic 1077 (35) 426 (33) 651 (37)
General hospital 1257 (41) 558 (43) 699 (39)
Private clinic 597 (19) 262 (20) 335 (19)
Private, not for proﬁt 138 (4.5) 53 (4) 85 (5)
Army 10 (0.3) 7 (0.5) 3 (0.2)
Centre with PCI on site 2789 (91) 1125 (86) 1664 (94) <0.001
Age 65.6614.4 68.2613.6 63.7614.6 <0.001
Age >75 years 960 (31) 488 (37) 472 (26) <0.001
Sex (female) 829 (27) 388 (30) 441 (25) 0.003
Risk factors
Hypertension 1653 (54) 805 (62) 848 (48) <0.001
Hypercholesterolaemia 1328 (43) 619 (47) 709 (40) <0.001
Diabetes mellitus 653 (21) 346 (26.5) 307 (17) <0.001
Current smoking 1035 (34) 328 (25) 707 (40) <0.001
Family history 768 (25) 318 (24) 450 (25) 0.513
Cardiovascular history
No known CAD 2293 (74.5) 838 (64) 1455 (82) <0.001
Previous MI 498 (16) 293 (22) 205 (12) <0.001
Previous PCI 489 (16) 303 (23) 186 (10.5) <0.001
Previous CABG 212 (7) 112 (9) 100 (6) 0.026
History of heart failure 146 (5) 94 (7) 52 (3) <0.001
History of stroke or TIA 139 (4.5) 68 (5) 71 (4) 0.112
Peripheral artery disease 244 (8) 154 (12) 90 (5) <0.001
Medications used before event
Aspirin 696 (23) 402 (31) 294 (17) <0.001
Thienopyridine 398 (13) 263 (20) 135 (7) <0.001
Statin 864 (28) 468 (36) 396 (22) <0.001
b-blocking agent 738 (24) 399 (31) 339 (19) <0.001
ACE-inhibitor or angiotensin II receptor blockers 1030 (33.5) 552 (40.5) 478 (28) <0.001
CABG: coronary artery bypass graft surgery; CAD, coronary artery disease; GRACE, Global registry of acute coronary events; LBBB, left bundle branch block; MI, myocardial infarction; NSTEMI,
non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; TIA, transient ischaemic attack.
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RegistryPhD), using the SAS V.8.2 (SAS Institute), STATA (V.9), NCSS,
or IBM-SPSS V.20.0 (IBM) softwares.
Strengths and weaknesses
The main strength of the present registry is that detailed data
were recorded to characterise the patients, their management
and outcomes. Overall more than 385 ﬁelds had to be ﬁlled-in,
not counting the totality of the medications used (including
doses for oral medications). The percentage of institutions
participating in the registry was high. We could not include,
however, centres from overseas French territories, so that our
data are illustrative of Metropolitan France only.
Though the cardiologists were asked not to modify their
therapeutic approach, we have no way to make sure that
participating in the registry had absolutely no impact on prac-
tices. As we committed not to divulge the data of individual
centres to anyone beside the clinicians in the centres themselves,
however, there was no incentive for them to change their habits.
Contrary to mandatory registries, FAST-MI was based upon
the voluntary participation of the centres. It therefore cannot
pretend to represent an exhaustive collection of AMI patients
during the study period. Of note, most centres not participating
were low-volume centres, so that our data are likely skewed
towards management practices that are mostly used in larger-
volume centres. Major bias, however, is unlikely. In a population
of AMI patients collected from medico-administrative databases
during the ﬁrst 6 months of 2006, mean age was 65 years
12;i n
2010, national data based on the ICD I21, I22 and I23 codes
found a mean age of 68.0 years and 33% women (data from the
Institut National de Veille Sanitaire). Overall, it is likely that
some patients, (eg, very elderly) were hospitalised outside
cardiology departments, or may have been admitted to smaller
hospitals and therefore not included in our registry. The clinical
outcomes in FAST-MI must be interpreted in this context.
Temporal comparisons with previous French surveys using the
same methodology, however, should not be affected by this
potential bias, which was common to all previous surveys.
RESULTS
Inclusion process
The inclusion process is summarised in ﬁgure 2. From a popula-
tion of 4970 patients screened for participation in the registry,
552 were excluded because they had one or more exclusion
criteria, had no myocardial infarction or were not admitted
during the survey timeframe, and 249 (5.6%) did not consent to
participate; 3079 were included during the ﬁrst 31 days. Further
analyses will describe the population admitted to the totality of
participating centres, during the ﬁrst 31 days.
Table 2 Index acute myocardial infarction, initial presentation and management
Whole population
(N[3079), N (%)
NSTEMI (N[1306),
N (%)
STEMI or presumed
new LBBB (N[1773), N (%) p Value
Admission parameters
Typical chest pain 2568 (83) 1036 (79) 1532 (86) <0.001
Initial Killip class <0.001
I 2457 (83) 1023 (81) 1434 (84)
II 301 (10) 124 (10) 177 (10)
III 153 (5) 91 (7) 62 (4)
IV 63 (2) 21 (2) 42 (2)
GRACE score 142637 (n¼2879) 138638 (n¼1216) 145636 (n¼1663) <0.001
Time delays (minutes)
Time from onset to ﬁrst call or contact
Median [25th; 75th percentiles]
90 [30; 300] 105 [30; 390] (n¼1257) 74 [30; 240] (n¼1727) <0.001
Procedures and management
Coronary angiography 2884 (94) 1185 (91) 1699 (96) <0.001
PCI 2380 (77) 859 (66) 1521 (86) <0.001
Fibrinolysis in STEMI patients
No 1532 (86)
Pre-hospital 137 (8)
In-hospital 104 (6)
Primary PCI in STEMI patients
Performed 1073 (64)
Intended 1171 (70)
Coronary artery bypass grafting 89 (3) 66 (5.1) 23 (1.3) <0.001
Medications in ﬁrst 48 h
Aspirin 2956 (96) 1256 (96) 1700 (96) 0.686
Clopidogrel 2474 (80) 1139 (87) 1335 (75) <0.001
Prasugrel 743 (24) 179 (14) 564 (32) <0.001
Glycoprotein IIb/IIIa inhibitors 1062 (34.5) 318 (24) 744 (42) <0.001
Low molecular weight heparin 1887 (61) 784 (60) 1103 (62) 0.220
Unfractionated heparin 1705 (55) 656 (50) 1049 (59) <0.001
Fondaparinux 518 (17) 247 (19) 271 (15) 0.008
Bivalirudin 102 (3) 21 (2) 81 (5) <0.001
Statin 2704 (88) 1114 (85) 1590 (90) <0.001
b-blocking agents 2439 (79) 1015 (78) 1424 (80) 0.079
ACE-I or ARB 1949 (63) 804 (62) 1145 (65) 0.086
ARB, angiotensin II receptor blocker; CABG: coronary artery bypass graft surgery; CAD, coronary artery disease; GRACE, Global registry of acute coronary events; LBBB, left bundle branch
block; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; TIA,
transient ischaemic attack.
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RegistryBaseline characteristics
Mean age of the whole population was 66614 years, and STEMI
patients were 4.5 years younger than patients with NSTEMI; 27%
of the patients were women. The prevalence of risk factors was
related to the type of infarction with more patients with hyper-
tension, hyperlipidaemia, and diabetes mellitus in the NSTEMI
population, and more current smokers among STEMI patients.
The current episode of MI was the ﬁrst clinical manifestation of
coronary artery disease in 75% of the patients (table 1).
About one out of four patients were on statins, b-blockers, or
aspirin at the time of their AMI.
Initial presentation and early management
Typical chest pain was present in 83%; 17% presented with
Killip class II or higher; the location of AMI was anterior in
37% of the STEMI patients. Mean GRACE score was 142637
(table 2).
The median time from symptom onset to ﬁrst call was
90 min, and was shorter (74 min) in STEMI patients. In STEMI
patients, median time from qualifying ECG to primary PCI was
110 min, and time from ECG to intravenous ﬁbrinolysis was
22 min.
Overall, 94% of the patients underwent coronary angiog-
raphy, and PCI was used in 77%. In STEMI patients, 14% were
treated with ﬁbrinolytic agents and 64% had primary PCI with
an additional 6% referred for intended primary PCI but no PCI
actually performed.
In-hospital complications
The mean duration in ICCU was 4.5 days, and mean hospital
stay was 8 days. Ten per cent of the patients had a maximal
Killip class III or IV at any time during the acute phase. Recur-
rent MI and stroke were rare. Overt bleeding was found in 7% of
the patients, with 4% needing blood transfusion. TIMI major
bleeding was present in 2.3% and TIMI minor bleeding in 2.7%
(table 3).
In-hospital death was 3.4% in the whole population, higher in
STEMI patients (4.5% vs 1.9%, p<0.001).
Medications prescribed and procedures scheduled at discharge
In the 2975 patients who were discharged alive, 36% were
scheduled for a rehabilitation programme (26% for NSTEMI and
44% for STEMI patients) (table 4).
Medications prescribed at discharge comprised aspirin in 96%,
with dual antiplatelet therapy in 87%, statins in 91%, beta-
blockers in 86%, ACE-inhibitors or ARBs in 80%. More STEMI
patients received recommended medications.
CONCLUSION
The FAST-MI 2010 survey gives a global picture of the way
patients with STEMI and NSTEMI were managed in France at
the end of 2010. Since 2005, regional networks have been
implemented in most French regions, with most patients now
admitted or transferred to hospitals with catheterisation labora-
tories. Many smaller hospitals no longer provide onsite care for
STEMI patients, who are immediately transferred to larger
centres using mobile intensive care units (Service d’Aide Médicale
Urgente, SAMU).
Compared with the previous French surveys, the use of
coronary angiography has continued to grow, with over 90% of
the patients undergoing coronary angiography during their
initial hospital stay.
8e10 Approximately 80% of STEMI patients
receive reperfusion therapy, and primary PCI has become the
predominant method of reperfusion.
13e15 These results are in
Table 4 Medications prescribed at discharge
Whole population (N[2962), N (%) NSTEMI (N[1275), N (%)
STEMI or presumed new
LBBB (N[1687), N (%) p Value
Aspirin 2841 (96) 1203 (94) 1638 (97) <0.001
Clopidogrel 1852 (62) 872 (68) 980 (58) <0.001
Prasugrel 798 (27) 206 (16) 592 (35) <0.001
Dual antiplatelet therapy 2576 (87) 1039 (81) 1537 (91) <0.001
Statin 2699 (91) 1134 (89) 1565 (93) <0.001
Beta-blocker 2547 (86) 1045 (82) 1502 (89) <0.001
ACE-I or ARB 2361 (80) 949 (74) 1412 (84) <0.001
CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; GRACE, Global registry of acute coronary events; LBBB, left bundle branch block; MI, myocardial infarction; NSTEMI,
non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; TIA, transient ischaemic attack.
Table 3 In-hospital evolution and complications
Whole population (N[3079), N (%) NSTEMI (N[1306), N (%)
STEMI or presumed new
LBBB (N[1773), N (%) p Value
Maximal Killip class during stay: <0.001
I 2435 (79) 1025 (78.5) 1410 (79.5)
II 331 (11) 142 (11) 169 (11)
III 191 (6) 104 (8) 87 (5)
IV 122 (4) 35 (3) 87 (5)
LVEF (%) 51.4611.4 (n¼2601) 54611 (n¼1092) 50611 (n¼1509) <0.001
Recurrent myocardial infarction 35 (1) 16 (1) 19 (1) 0.691
Stroke 14 (0.5) 2 (0.2) 12 (0.7) 0.033
Any bleeding or transfusion 333 (11) 151 (12) 182 (10) 0.252
TIMI major bleeding 71 (2.3) 28 (2.1) 43 (2.4) 0.607
TIMI minor bleeding 82 (2.7) 28 (2.1) 54 (3.0) 0.125
In-hospital death 104 (3.4) 25 (1.9) 79 (4.5) <0.001
LVEF, left ventricular ejection fraction; ICU, intensive care unit; TIMI, Thrombolysis in Myocardial Infarction.
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Registrykeeping with the trend observed in other countries, and the
ﬁgures are concordant with those recently reported from the
Swedish registry.
16 The rates of prescription of recommended
medications are high, comparable to those reported in the
MINAP
17 and Get With the Guidelines
18 registries.
Finally, complication rates and in-hospital mortality have
declined markedly, in comparison with the previous French
surveys performed using a similar methodology.
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